natgillin/translations-raw huggingface dataset:
Everolimus trough concentrations should be assessed approximately 2 weeks after the addition of a moderate CYP3A4 or PgP inhibitor.
Najnižjo koncentracijo everolimusa pred naslednjim odmerjanjem je treba oceniti približno 2 tedna po uvedbi dodatnega zdravljenja z zmernim zaviralcem CYP3A4 ali
everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of these medicinal products
everolimus, sirolimus (imenovan tudi rapamicin) zaradi povečanja koncentracij teh zdravil v plazmi,
eversion of the eyelid, eye movement disorder, eyelid irritation
izvihanje veke, moteno gibanje zrkla, draženje vek
Every 12 hours
na 12 ur
every 2 months until seroconversion following vaccination.
vsaka dva meseca do serokonverzije po cepljenju
Every 2 weeks
na 2 tedna
every 2 weeks
vsak drugi teden
every 2 weeks during the first 12 months of therapy,
vsake 2 tedna v prvih 12 mesecih zdravljenja,
every 2-4 weeks
vsake 2 do 4 tedne
Every 24 hours
na 24 ur
Every 24 hours (12 to 24 hours for
Na vsakih 24 ur (12 do 24 ur
Every 24 hours (12 to 24 hours for
Na vsakih 24 ur (12 do 24 ur za
Every 24 hours*
vsakih 24 ur
Every 24 hours, at least 1 day, until
Vsakih 24 ur, vsaj 1 dan, dokler se
Every 24 hours, at least 1 day, until healing is achieved.
Vsakih 24 ur, vsaj 1 dan, dokler ni doseženo celjenje.
every 3 - 4 weeks
na vsake 3–4 tedne
every 3 - 4 weeks
po alogenski transplantaciji hematopoetskih
every 3 - 4 weeks to obtain IgG trough level above 5 g/l
Hipogamaglobulinemija (< 4 g/l) pri bolnikih
every 3 - 4 weeks to obtain IgG trough level above 5 g/l
najnižje ravni IgG nad 5 g/l
every 3 - 4 weeks to obtain IgG trough level of at least 5 - 6 g/l
najnižje ravni IgG vsaj 5–6 g/l
every 3 - 4 weeks to obtain IgG trough level of at least 5 - 6 g/l
vsake 3–4 tedne za doseganje
every 3 to 4 weeks
vsake 3 do 4 tedne
every 3 to 4 weeks to obtain IgG trough level above 5 g/l
vsake 3 do 4 tedne, da se doseže najnižja raven IgG nad 5 g/l
every 3 to 4 weeks to obtain IgG trough level above 5 g/l.
vsake 3 do 4 tedne, da se doseže najnižja raven IgG nad 5g/l
every 3 weeks over 1-2 days
vsake 3 tedne 1–2 dni
every 3-4 weeks
vsake 3-4 tedne
every 3-4 weeks to obtain IgG trough level above 5g/l
vsake 3 do 4 tedne, da dosežete najnižjo koncentracijo IgG vsaj 5 g/l
every 3-4 weeks to obtain IgG trough level of at least 5-6 g/l
vsake 3 do 4 tedne, da dosežete najnižjo koncentracijo IgG vsaj 5-6 g/l
Every 4 Week (Q4W) Dosing Regimen
Odmerna shema na 4 tedne
Every 4 weeks (± 3 days) starting at end of week 16 after transplantation 5 mg/kg
Vsake 4 tedne (± 3 dni), s pričetkom konec 16. tedna po presaditvi 5 mg/kg
Every 4 weeks (± 3 days), starting at the end of week 16 after transplantation 5 mg/kg
Vsake 4 tedne (± 3 dni), s pričetkom konec 16. tedna po presaditvi 5 mg/kg
every 4 weeks during the following 6 months of therapy, every 8 weeks during further treatment.
vsake 4 tedne naslednjih 6 mesecev, ter vsakih 8 tednov v nadaljevanju zdravljenja.
every 4 weeks N=69
vsake 4 tedne
every 4-8 weeks
vsakih 4 do 8 tednov
every 4-8 weeks
vsakih 4 do 8 tednov.
Every 40 to 45 days, a refill of insulin at the hospital is needed.
Na 40 do 45 dni morate opraviti ponovno polnjenje z insulinom v bolnišnici.
Every 48 hours
na 48 ur
Every 6 to 8 weeks depending on your disease
vsakih 6 do 8 tednov, odvisno od vaše bolezni
Every 6 to 8 weeks depending on your disease
vsakih 6 to 8 tednov, odvisno od vaše bolezni
Every 8
na 8 ur
Every 8 hours
na 8 ur
every 8 hours is
600 mg na vsakih 8 ur.
every 8 weeks
vsakih 8 tednov
Every 9 months, as described for primary vaccination, based on a duration of immunity of 280 days.
Vsakih 9 mesecev, kot je opisano za osnovno cepljenje, na osnovi trajanja imunosti 280 dni.
Every 9 months, as described for primary vaccination, based on duration of immunity of 280 days.
Vsakih 9 mesecev, kot je opisano za osnovno cepljenje, na osnovi trajanja imunosti 280 dni.
Every day you have to check that the medicine is clear, add a new needle, take the injection in your abdomen and then throw away the needle before storing your pre-filled pen in the refrigerator (2-8°C).
Vsak dan morate preveriti, če je zdravilo bistro, dodati novo iglo, se zbosti v trebuh in nato zavreči iglo, preden shranite napolnjen injekcijski peresnik v hladilnik (2 °C -8 °C).
Every four weeks
vsake štiri tedne
Every Genuair inhaler will deliver at least 30 or 60 doses, depending on the pack size.
En inhalator Genuair vsebuje vsaj 30 ali 60 odmerkov, odvisno od velikosti pakiranja.
Every Genuair inhaler will deliver at least 60 doses.
Vsak inhalator Genuair vsebuje vsaj 60 odmerkov.
Every increase in dose or any dose adjustment to your baby’s weight must be done by your doctor.
Vsako povečanje ali prilagoditev odmerka na dojenčkovo težo mora izvesti zdravnik.
Every injection should be followed by a flush with 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.
Vsakemu injiciranju sledi izpiranje s 5 ml 9 mg/ml (0,9%) raztopine natrijevega klorida za injiciranje.
every month for the first year of treatment at regular intervals decided by your doctor after the first year of treatment.
vsak mesec med prvim letom zdravljenja, po prvem letu zdravljenja pa v rednih presledkih, ki jih bo določil zdravnik.
Every one or two weeks, the doctor may adjust your dose to find your individual maintenance dose.
Vsak teden ali na dva tedna bo zdravnik morda prilagodil vaš odmerek, da bo določil vaš individualni vzdrževalni odmerek.
Every other day (once every two days), 1.0 ml of the prepared Betaferon solution (see Annex ‘Self- injection procedure’ in the second part of this leaflet) injected under the skin (subcutaneously).
Vsak drugi dan (enkrat na dva dni) 1 ml pripravljene raztopine zdravila Betaferon (glejte Dodatek: Postopek samoinjiciranja v drugem delu tega navodila), injicirane pod kožo (subkutano).
Every time you are given Yondelis for the treatment of soft tissue sarcoma, it will take about 24 hours for all of the solution to enter your blood.
Vsakič, ko prejmete zdravilo Yondelis za zdravljenje sarkoma mehkega tkiva, bo trajalo okoli 24 ur, da vsa raztopina vstopi v vašo kri.
Every time you use a KwikPen you must use a new needle.
Ob vsaki uporabi KwikPena morate uporabiti novo iglo.
Every time you use a new pen
Vsakič, ko uporabite nov injekcijski peresnik
Every time you use a new pen
Vsakokrat, ko uporabite nov injekcijski peresnik
Every two months for two years or until disease progression (whichever occurs first)
Vsaka dva meseca v obdobju dveh let ali do napredovanja bolezni (kar se zgodi prej)
Every two weeks
vsaka dva tedna
every two weeks during the first six months of treatment, and every 8 weeks thereafter (see section 4.4).
(vsaka dva tedna) v prvih 6 mesecih zdravljenja in potem vsakih 8 tednov (glejte poglavje 4.4).
every two weeks during the first six months of treatment, and every 8 weeks thereafter (see section 4.4).
vsaka dva tedna v prvih 6 mesecih zdravljenja in potem vsakih 8 tednov (glejte poglavje 4.4).
every week
vsak teden
Every week during the first month of initiation of treatment or after therapy modification
vsak teden v prvem mesecu po uvedbi ali spremembi zdravljenja,
every week for the first 8 weeks of treatment at least every month after that for as long as you are taking Imnovid.
vsak teden v prvih 8 tednih zdravljenja, po tem pa najmanj enkrat mesečno, dokler jemljete zdravilo Imnovid.
Every week for the first four weeks, your doctor will administer an intravenous infusion of diluted Soliris.
Prve štiri tedne vam bo zdravnik vsak teden dal intravensko infuzijo razredčenega zdravila Soliris.
Every year, the European Medicines Agency (EMA) will review additional information that will become available according to an agreed timetable and this summary will be updated as necessary.
Evropska agencija za zdravila (EMA) bo vsako leto pregledala razpoložljive dodatne informacije glede na sprejet časovni načrt in po potrebi posodobila ta povzetek.
Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.
Evropska agencija za zdravila bo vsako leto ponovno pregledala vse razpoložljive nove podatke o zdravilu in ustrezno posodobila ta povzetek.
Every year, the European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary.
Evropska agencija za zdravila bo vsako leto pregledala vse razpoložljive nove podatke in ustrezno posodobila ta povzetek.
Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Evropska agencija za zdravila bo pregledala vse nove podatke, ki bi morda postali dostopni, in po potrebi posodobila ta povzetek.
Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Evropska agencija za zdravila bo vsako leto pregledala vse razpoložljive nove informacije in po potrebi posodobila ta povzetek.
Everyone who takes Foscan will become sensitive to light for about 15 days after injection.
Vsi bolniki, ki jemljejo zdravilo Foscan, bodo po injiciranju za približno 15 dni postali preobčutljivi na svetlobo.
EVG = elvitegravir; COBI = cobicistat; FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable
EVG = elvitegravir; COBI = kobicistat; FTC = emtricitabin; TAF = alafenamidtenofovirat fumarat; TFV = tenofovir n/v = ne velja
EVICEL is also indicated as suture support for haemostasis in vascular surgery and for suture line sealing in dura mater closure.
Zdravilo EVICEL je indicirano tudi za podporo šivom za doseganje hemostaze pri žilnih kirurških posegih in za lepljenje šivov pri zapiranju dure.
EVICEL is applied during surgical operations, to reduce bleeding and oozing during and after the operation.
Zdravilo EVICEL se uporablja med kirurškimi posegi za zmanjšanje krvavitev in izcejanja med posegom in po njem.
EVICEL is available in the following sizes: 2 x 1 ml, 2 x 2 ml, and 2 x 5 ml.
Zdravilo EVICEL je na voljo v pakiranjih naslednjih velikosti: 2 x 1 ml, 2 x 2 ml in 2 x 5 ml.
Evicel is then dripped or sprayed on the surface of the wound until it forms a thin layer.
Zdravilo Evicel se nato nakapa ali naprši na površino rane, dokler se ne ustvari tanek sloj.
EVICEL is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis (see Section 5.1).
Zdravilo EVICEL se uporablja kot podporno zdravljenje za izboljšanje hemostaze pri kirurških posegih, kjer standardne kirurške tehnike ne zadoščajo (glejte poglavje 5.1).
Evicel must also not be used as a glue for the fixation of dural patches (material which is sewn over an opening in the dura mater).
Ne sme se uporabljati niti kot lepilo za pritrditev duralnih obližev (materiala, ki se prišije prek odprtine v duri mater).
Evicel must also not be used in dura mater closure if the dura mater cannot be sutured, or if there are gaps greater than 2 mm after suturing.
Zdravilo Evicel se prav tako ne sme uporabljati pri celjenju dure mater, če se te ne da zašiti ali če so po šivanju odprtine še vedno večje od 2 mm.
EVICEL must not be used as a glue for the fixation of dural patches.
Zdravilo EVICEL se ne sme uporabljati kot lepilo za pritrjanje duralnih presadkov.
EVICEL must not be used as a sealant when the dura mater cannot be sutured.
Zdravilo EVICEL se ne sme uporabljati kot lepilo, kadar dure ni mogoče šivati.
EVICEL must not be used for sealing the suture line in dura mater if there are gaps of greater than 2 mm after suturing.
Zdravilo EVICEL se ne sme uporabljati za lepljenje šiva v duri, če so po šivanju odprtine, večje od 2 mm.
EVICEL should not be used in endoscopic surgery.
Zdravila EVICEL se ne sme uporabljati pri endoskopskih kirurških posegih.
EVICEL should only be applied using the CE-marked EVICEL application device and optional use of a tip accessory to the device.
Zdravilo EVICEL se sme nanesti samo z aplikatorjem EVICEL, ki ima oznako CE, in z izbirno uporabo nastavka na aplikatorju.
EVICEL should only be applied using the CE-marked EVICEL application device and optional use of accessory tips to the device.
Zdravilo EVICEL se sme nanašati samo z aplikatorjem EVICEL, ki ima oznako CE, in z izbirno uporabo nastavkov na aplikatorju.
EVICEL will be applied as a thin layer.
Zdravilo EVICEL se nanaša v tankem sloju.
Evidence from clinical studies shows that lamivudine plus zidovudine delays the emergence of zidovudine resistant isolates in individuals with no prior antiretroviral therapy.
Podatki iz kliničnih študij kažejo, da kombinacija lamivudina in zidovudina zakasni pojav izolatov, odpornih na zidovudin, pri posameznikih, ki pred tem še niso prejemali protiretrovirusnega zdravljenja.
Evidence from similar active substances in humans suggests that accidental administration to cattle of more than the authorised dose could result in adverse reactions, which are related to the activity of pegbovigrastim.
Dokazi, zbrani za podobne zdravilne učinkovine pri ljudeh, nakazujejo, da nenamerna uporaba odmerka, večjega od predpisanega, lahko povzroči neželene učinke, ki so povezani z aktivnostjo pegbovigrastima.
evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days of treatment
znaki krvavitve v prebavilih, obilno krvavitvijo v sečilih ali spolnih organih ali kako drugo aktivno nenormalno krvavitvijo, ki nastopi v zadnjih 30 dneh pred zdravljenjem;
Evidence of liver disease or increased liver enzymes
znaki bolezni jeter ali povišane ravni jetrnih encimov,
Evidence of obstructive biliary tract disease should be ruled out in patients with elevations of ALT and AST or in patients with a prior history of treatment with any somatostatin analogue.
Pri bolnikih z zvečano koncentracijo ALT in AST oz. bolnikih, ki so se že zdravili s kakšnim somatostatinskim analogom, je treba izključiti obstruktivno bolezen biliarnega trakta.
Evidence of paediatric efficacy was seen in a dose-controlled ICU study in a largely post-operative population aged 1 month to ≤ 17 years.
Dokaz o učinkovitosti zdravila pri pediatričnih bolnikih so opazili pri z odmerkom nadzorovani študiji, opravljeni na oddelku za intenzivno nego, na večinoma postoperativni populaciji v starosti od 1 meseca do ≤ 17 let.
Evidence of the efficacy of propranolol in patients with high- risk haemangioma is available both in literature and in a specific compassionate use program performed with Hemangiol.
Dokazi o učinkovitosti propranolola pri bolnikih s hemangiomom z visoko stopnjo tveganja so na voljo v literaturi in v specifičnem programu sočutne uporabe, izvedenim z zdravilom Hemangiol.
Evidence of the teratogenicity of 6–mercaptopurine in humans is equivocal.
Dokazi o teratogenosti 6-merkaptopurina pri ljudeh niso zanesljivi.
Evidence suggests that taking oestrogen-only HRT possibly increases the risk of breast cancer.
Zbrani dokazi kažejo na možno zvečano tveganje za raka dojke pri ženskah, ki uporabljajo hormonsko nadomestno zdravljenje (HNZ), ki vsebuje samo estrogen.
Eviplera 200 mg/25 mg/245 mg film-coated tablets
Eviplera 200 mg/25 mg/245 mg filmsko obložene tablete
Eviplera [outer packaging only]
Eviplera [samo na zunanji ovojnini]
Eviplera arm n = 317
Krak z zdravilom Eviplera n = 317
Eviplera contains a colourant called sunset yellow aluminium lake (E110), which may cause allergic reactions.
Zdravilo Eviplera vsebuje oranžno barvilo FCF (E110), ki lahko povzroči alergijske reakcije.
Eviplera contains sunset yellow aluminium lake also called “E110” which may cause allergic reactions.
Zdravilo Eviplera vsebuje barvilo sončno rumeno FCF (E110), ki lahko povzroči alergijske reakcije.
Eviplera contains three active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; rilpivirine, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); and tenofovir disoproxil, which is a ‘prodrug’ of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
Zdravilo Eviplera vsebuje tri zdravilne učinkovine: emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, rilpivirin, ki je nenukleozidni zaviralec reverzne transkriptaze (NNRTI), in dizoproksiltenofovirat, ki je predzdravilo tenofovirja, kar pomeni, da se v zdravilno učinkovino tenofovir pretvori v telesu.
Eviplera emtricitabine / rilpivirine / tenofovir disoproxil
Eviplera emtricitabin/rilpivirin/dizoproksiltenofovirat
Eviplera has no or negligible influence on the ability to drive and use machines.
Zdravilo Eviplera nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Eviplera has not been studied in patients over the age of 65 years.
Zdravila Eviplera niso preučili pri bolnikih, starejših od 65 let.
Eviplera is a treatment for Human Immunodeficiency Virus (HIV) infection in adults aged 18 years and over.
Eviplera je zdravilo za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti (HIV) pri odraslih, starih 18 let in več.
Eviplera must not be used in combination with products containing St John’s wort as co- administration may cause significant decreases in rilpivirine plasma concentrations.
Zdravila Eviplera ni dovoljeno uporabljati v kombinaciji z zdravili, ki vsebujejo šentjanževko, saj lahko sočasna uporaba povzroči pomembno zmanjšanje koncentracij rilpivirina v plazmi.
Eviplera should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes.
Zdravilo Eviplera je treba uporabljati previdno, če se uporablja sočasno z zdravili z znanim tveganjem za Torsade de Pointes.
Eviplera should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
Zdravilo Eviplera je treba uporabljati previdno pri sočasnem dajanju zdravil z znanim tveganjem za Torsade de Pointes.
Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil fumarate or tenofovir alafenamide.
Zdravila Eviplera ne sme sočasno uporabljati z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirijev fumarat ali alafenamidtenofovirijev fumarat.
Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Zdravila Eviplera se ne sme dajati skupaj z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirijev fumarat, alafenamidtenofovirijev fumarat ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.5).
Eviplera should not be co-administered with the following medicinal products as significant decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Eviplera:
Zdravila Eviplera ni dovoljeno dajati sočasno z naslednjimi zdravili, saj lahko pride do znatnega zmanjšanja koncentracij rilpivirina v plazmi (zaradi indukcije encima CYP3A ali povečanja vrednosti pH v želodcu), kar lahko izniči terapevtski učinek zdravila Eviplera:
evir/riton
(0,96-1,31)
evir/riton
1,01 (0,91-1,11)
evir/riton
tonavir
evir/riton
tonavir.
evir/riton avir
0,90 (0,81-1,01)
evir/riton avir
tonavir
Evista (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials.
Zdravilo Evista (n = 317) so v nekaterih kliničnih preskušanjih primerjali s kontinuirano kombinirano (n = 110) hormonsko nadomestno terapijo (HRT – hormone replacement therapy) ali s ciklično HRT (n = 205).
Evista 60 mg film coated tablets
Evista 60 mg filmsko obložene tablete
EVISTA 60 mg film coated tablets raloxifene hydrochloride
EVISTA 60 mg filmsko obložene tablete raloksifenijev klorid
Evista are white, oval, film coated tablets which are marked with the number 4165.
Evista so bele, ovalne, filmsko obložene tablete, ki so označene s številko 4165.
Evista contains lactose
Zdravilo Evista vsebuje laktozo.
Evista contains the active substance raloxifene hydrochloride.
Zdravilo Evista vsebuje zdravilno učinkovino raloksifenijev klorid.
Evista has no or negligible effects on driving or using machines.
Zdravilo Evista nima učinkov ali ima zanemarljive učinke na vožnjo ali upravljanje s stroji.
Evista is intended for long-term use.
Zdravilo Evista je namenjeno za dolgotrajno uporabo.
Evista must not be taken by women of child bearing potential.
Zdravila Evista ne smejo jemati ženske v rodni dobi.
Evista reduced the incidence of clinical vertebral fractures by 35% compared with placebo (HR 0.65, CI 0.47 0.89).
Zdravilo Evista je zmanjšalo incidenco kliničnih zlomov vretenc za 35 % v primerjavi s placebom (HR 0,65, CI 0,47– 0,89).
Evista should not be used in patients with hepatic impairment (see section 4.3 and 4.4).
Zdravila Evista ne smemo uporabljati pri bolnikih z jetrno okvaro (glejte poglavje 4.3 in 4.4).
Evista treatment for 4 years reduced the incidence of vertebral fractures by 46 % (RR 0.54, CI 0.38, 0.75) and 32 % (RR 0.68, CI 0.56, 0.83) in patients with osteoporosis or osteoporosis with an existing fracture respectively.
Štiriletno zdravljenje z zdravilom Evista je pri bolnicah z osteoporozo zmanjšalo incidenco zlomov vretenc za 46 % (RR 0,54 pri 95 % CI 0,38–0,75), pri bolnicah z osteporozo in obstoječim zlomom pa je incidenca zmanjšana za 32 % (RR 0,68 pri 95 % CI 0,56–0,83).
Evolocumab has been designed to attach to a protein called ‘PCSK9’.
Evolokumab so razvili tako, da se veže na beljakovino, imenovano „PCSK9“.
Evolocumab is designed to attach to a substance called PCSK9 that affects the liver’s ability to take in cholesterol.
Evolokumab je zasnovan za vezavo na snov, ki jo imenujemo PCSK9 in vpliva na sposobnost jeter, da sprejemajo holesterol.
Evoltra 1 mg/ml concentrate for solution for infusion
Evoltra 1 mg/ml koncentrat za raztopino za infundiranje
Evoltra 1 mg/ml concentrate for solution for infusion clofarabine
Evoltra 1 mg/ml koncentrat za raztopino za infundiranje klofarabin
Evoltra has been authorised under ‘exceptional circumstances’.
Zdravilo Evoltra je pridobilo dovoljenje za promet v „izjemnih okoliščinah”.
Evoltra is a concentrate for solution for infusion.
Zdravilo Evoltra je koncentrat za raztopino za infundiranje.
Evoltra may not be suitable for you:
Zdravilo Evoltra morda ni primerno za vas:
EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) was a randomised, double-blind clinical study evaluating cinacalcet HCl vs. placebo for the reduction of the risk of all-cause mortality and cardiovascular events in 3,883 patients with secondary HPT and CKD receiving dialysis.
Študija EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) je bila randomizirana, dvojno slepa klinična študija, v kateri so ocenjevali cinakalcet klorid v primerjavi s placebom za zmanjšanje tveganja za umrljivost zaradi vseh vzrokov in za kardiovaskularne dogodke pri 3.883 bolnikih s sekundarnim hiperparatiroidizmom in kronično boleznijo ledvic, ki so na dializi.
EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) was a randomized, double-blind clinical study evaluating cinacalcet HCl vs. placebo for the reduction of the risk of all-cause mortality and cardiovascular events in 3,883 patients with secondary HPT and CKD receiving dialysis.
Študija EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) je bila randomizirana, dvojno slepa klinična študija, v kateri so ocenjevali cinakalcet klorid v primerjavi s placebom za zmanjšanje tveganja za umrljivost zaradi vseh vzrokov in za kardiovaskularne dogodke pri 3.883 bolnikih s sekundarnim hiperparatiroidizmom in kronično boleznijo ledvic, ki so na dializi.
EVOTAZ (see section 4.3).
zdravilom EVOTAZ je njihova
EVOTAZ 300 mg/150 mg film-coated tablets
EVOTAZ 300 mg/150 mg filmsko obložene tablete
EVOTAZ 300 mg/150 mg film-coated tablets atazanavir/cobicistat
EVOTAZ 300 mg/150 mg filmsko obložene tablete atazanavir/kobicistat
EVOTAZ and development of
zdravila EVOTAZ in razvoja